tert-butyl N-[2-(2-butoxyethoxy)ethyl]carbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl N-[2-(2-butoxyethoxy)ethyl]carbamate
• 化学式: C₁₃H₂₇NO₄
• 分子量: 261.36
• InChiKey: BFBHTUVAMYGYDN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  56.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Composition for inducing cell reprogramming
  申请人：GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY

  公开号：US10858321B2

  公开（公告）日：2020-12-08

  The present invention relates to a composition for inducing cell reprogramming. The indazole derivative compound contained in the composition of the present invention shows an improved biological profile and at the same time can perform efficient cell reprogramming. In addition, unlike conventional compounds (e.g. riversine or BIO) for inducing low-molecular cell reprogramming, the indazole derivative compound of the present invention does not show cytotoxicity and thus is expected to have high growth in the market of cell therapy products when clinically applied. Conventional indazole derivative compounds have never known as a use for cell reprogramming. Compared with conventional indazole derivative compounds, the compound of the present invention has a great cell reprogramming ability while having no or little cytotoxicity.

  本发明涉及一种用于诱导细胞重编程的组合物。本发明组合物中所含的吲唑衍生物化合物具有更好的生物学特性，同时可以进行高效的细胞重编程。此外，与用于诱导低分子细胞重编程的传统化合物（如河流碱或 BIO）不同，本发明的吲唑衍生物化合物不显示细胞毒性，因此在临床应用时有望在细胞治疗产品市场上获得高增长。传统的吲唑衍生物化合物从未用于细胞重编程。与传统的吲唑衍生物化合物相比，本发明的化合物具有很强的细胞重编程能力，同时没有或几乎没有细胞毒性。
• US9981954B2
  申请人：——

  公开号：US9981954B2

  公开（公告）日：2018-05-29